He has served as interim CEO since June, according to an Aug. 10 news release.
“Since creating Aziyo in 2015, Randy and I have worked together to build a company where regenerative medicine is used to its full potential,” Aziyo co-founder Kevin Rakin said in the release. “Randy is a visionary leader with a track record of creating significant shareholder value in regenerative medicine.”
Aziyo Biologics focuses on regenerative medicine for orthopedics, cardiology and reconstructive surgery. One of its products, the ViBone moldable cell bone matrix, debuted in spine surgery in January 2021.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.